The Cancer Letter

Inside information on cancer research and drug development

Guest Editorial

Herceptin: What it took to make it happen

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

One day in 1996, in my role as chief science correspondent for NBC News, I was rummaging through the usual huge (pre-internet) pile of press releases on my desk and zeroed in on one: a phase III trial of a treatment for an aggressive type of breast cancer that was desperate to accrue volunteers.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Robert Bazell
Adjunct professor of molecular, cellular and developmental biology, Yale University
Table of Contents

YOU MAY BE INTERESTED IN

Sponsored

Harnessing innovation: The next frontier in surgical oncology

The field of surgical oncology has undergone transformative advancements over the last decade. From refining minimally invasive techniques to leveraging immunotherapy and viral oncolytics, our collective goal remains the same: improving patient outcomes while reducing treatment burden. At City of Hope, we have prioritized accelerating the translation of laboratory discoveries into clinical applications, and nowhere is this more evident than in our work with oncolytic viruses, remote surgery, and the integration of AI in surgical decision-making.
By Yuman Fong
Byline
Robert Bazell
Adjunct professor of molecular, cellular and developmental biology, Yale University
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account